View Moleculin Biotech, Inc. MBRX investment & stock information. Get the latest Moleculin Biotech, Inc. MBRX detailed stock quotes, stock data, Real-Time About MBRX. Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin 7 Feb 2020 Houston biotech firm raises millions; pharma co. enacts reverse stock split Houston-based Moleculin Biotech Inc. (Nasdaq: MBRX), million shares of common stock at a combined public offering price of 80 cents per share. See Tweets about #mbrx on Twitter. $MBRX #MBRX Soaring with good volume. Target: $MBRX Moleculin, #stock shows exciting increase of +5.26% after 24 Apr 2019 MBRX raised $15 million by selling 9,375,000 units at a public offering price of $1.60 per unit in a registered direct offering. Each unit is MBRX Stock Price | Moleculin Biotech Inc. Stock Quote (U.S ... MBRX | Complete Moleculin Biotech Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Moleculin Biotech (MBRX) Stock Message Board - InvestorsHub Metabasis Therapeutics (NASDAQ:MBRX) Historical Stock Chart Moleculin Biotech (Nasdaq:MBRX), a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, will visit the Nasdaq MarketSite in Times Square to celebrate its initial public offering (IPO). Moleculin Biotech Inc. Stock Price (MBRX) | Barron's View today's stock price, news and analysis for Moleculin Biotech Inc. (MBRX). Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation and
MBRX Stock Price and Chart — NASDAQ:MBRX — TradingView Yesterdays gainers are quickly forgotten, up 170% on the 4/22/19 and loses drops 50% on 4/23/19 on news of new offering. Despite this a great opportunity may still exist in the name, tomorrow there is still scheduled call to announce developments in FDA approval and …
Moleculin Biotech (MBRX) Announces Proposed Underwritten Public Offering of Common Stock, Warrants. Article Related Press Releases (1) Related Articles (1) Stock Quotes (1) Comments (0)
Moleculin Announces Pricing Of Underwritten Public Offering Mar 27, 2019 · HOUSTON, March 27, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced the pricing of an underwritten public offering of an aggregate of 5,250,000 units at a public offering price of $1.00 per unit. MBRX Moleculin Biotech — Stock Price and Discussion ... Securities products and services offered to self-directed investors through ST Invest, LLC. Member FINRA / SIPC.ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal. Please read important legal disclosures. Moleculin down 51% on direct equity offering (NASDAQ:MBRX ...